{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T02:05:12Z","timestamp":1795053912251,"version":"4.10.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Colorectal cancer (CRC) is one of the most common malignant tumors with the highest incidence and mortality rates worldwide. Immune checkpoint blockade (ICB) therapy has revolutionized the landscape of cancer treatment; however, most patients with CRC gain limited benefits from it. The immunosuppressive microenvironment of CRC is an important cause of tumor progression, metastasis, and immunotherapy resistance. This study aimed to reveal the key role of chemokine receptor 4 (CXCR4) in the immunosuppressive microenvironment and glutamine metabolism reprogramming using integrated single-cell transcriptomics and metabolomics analyses. The in vivo and in vitro experiments verified that CXCR4 mediated metabolic reprogramming in CRC cells by regulating the PI3K-Akt-SMAD4 pathway. Further co-culture experiments revealed that CXCR4 promoted the polarization of tumor-associated macrophages (TAMs) to M2 type through glutamine metabolic reprogramming and induced the exhaustion of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, thereby intensifying immune escape. The knockdown of CXCR4 significantly increased the infiltration of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells and M1 TAMs, reduced the infiltration of M2 TAMs, effectively reshaped the immunosuppressive microenvironment of CRC-bearing mice, and significantly enhanced the immunotherapeutic effect against programmed cell death protein 1 (PD-1). This study discovered a novel mechanism by which CXCR4 drove CRC immune escape through the dual-axis regulation of the \u201cglutamine metabolism-immune microenvironment.\u201d Targeting CXCR4 not only inhibits tumor metabolic adaptability but also reverses TAMs polarization and T cell exhaustion, thereby effectively sensitizing PD-1 inhibitors. This study provides an important theoretical basis and a highly promising new combined treatment strategy for overcoming ICB resistance in patients with CRC.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08795-x","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:04:25Z","timestamp":1777910665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multi-omics reveals CXCR4 drives immune escape in colorectal cancer via metabolic reprogramming and immune microenvironment remodeling"],"prefix":"10.1038","volume":"17","author":[{"given":"Chengle","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3137-7440","authenticated-orcid":false,"given":"Yuting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaopeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4545-350X","authenticated-orcid":false,"given":"Ruonan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5809-6546","authenticated-orcid":false,"given":"Jiwen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruorong","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8542-4362","authenticated-orcid":false,"given":"Bo","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1413-8031","authenticated-orcid":false,"given":"Zixiang","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7538-0218","authenticated-orcid":false,"given":"Qingling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9646-320X","authenticated-orcid":false,"given":"Changjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"8795_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"8795_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"8795_CR3","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s11864-024-01194-4","volume":"25","author":"C Wang","year":"2024","unstructured":"Wang C, Liu X, Wang W, Miao Z, Li X, Liu D, et al. Treatment options for distal rectal cancer in the era of organ preservation. Curr Treat Options Oncol. 2024;25:434\u201352.","journal-title":"Curr Treat Options Oncol"},{"key":"8795_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10555-023-10158-3","volume":"43","author":"R Abedizadeh","year":"2024","unstructured":"Abedizadeh R, Majidi F, Khorasani HR, Abedi H, Sabour D. Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments. Cancer Metastasis Rev. 2024;43:729\u201353.","journal-title":"Cancer Metastasis Rev"},{"key":"8795_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1472772","volume":"15","author":"L Wang","year":"2024","unstructured":"Wang L, Zhang L, Zhang Z, Wu P, Zhang Y, Chen X. Advances in targeting tumor microenvironment for immunotherapy. Front Immunol. 2024;15:1472772.","journal-title":"Front Immunol"},{"key":"8795_CR6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11:933\u201359.","journal-title":"Cancer Discov"},{"key":"8795_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ccell.2022.02.013","volume":"40","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang Q, Xing B, Luo N, Gao R, Yu K, et al. Immune phenotypic linkage between colorectal cancer and liver metastasis. Cancer Cell. 2022;40:424\u201337.e5.","journal-title":"Cancer Cell"},{"key":"8795_CR8","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.bbamem.2006.11.002","volume":"1768","author":"JM Busillo","year":"2007","unstructured":"Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophysica Acta Biomembr. 2007;1768:952\u201363.","journal-title":"Biochim Biophysica Acta Biomembr"},{"key":"8795_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","volume":"124","author":"S Chatterjee","year":"2014","unstructured":"Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31\u201382.","journal-title":"Adv Cancer Res"},{"key":"8795_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-pharmtox-010919-023340","volume":"61","author":"MJ Smit","year":"2021","unstructured":"Smit MJ, Schlecht-Louf G, Neves M, van den Bor J, Penela P, Siderius M, et al. The CXCL12\/CXCR4\/ACKR3 axis in the tumor microenvironment: signaling, crosstalk, and therapeutic targeting. Annu Rev Pharmacol Toxicol. 2021;61:541\u201363.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"8795_CR11","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.7150\/ijbs.82317","volume":"19","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li J, Lei W, Wang H, Ni Y, Liu Y, et al. CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications. Int J Biol Sci. 2023;19:3341\u201359.","journal-title":"Int J Biol Sci"},{"key":"8795_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1450441","volume":"15","author":"T Gao","year":"2024","unstructured":"Gao T, Yang L, Zhang Y, Bajinka O, Yuan X. Cancer metabolic reprogramming and precision medicine-current perspective. Front Pharmacol. 2024;15:1450441.","journal-title":"Front Pharmacol"},{"key":"8795_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70120","volume":"6","author":"MA Kumar","year":"2025","unstructured":"Kumar MA, Baba SK, Khan IR, Khan MS, Husain FM, Ahmad S, et al. Glutamine metabolism: molecular regulation, biological functions, and diseases. MedComm. 2025;6:e70120.","journal-title":"MedComm"},{"key":"8795_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217089","volume":"598","author":"MM Allevato","year":"2024","unstructured":"Allevato MM, Trinh S, Koshizuka K, Nachmanson D, Nguyen TC, Yokoyama Y, et al. A genome-wide CRISPR screen reveals that antagonism of glutamine metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell death. Cancer Lett. 2024;598:217089.","journal-title":"Cancer Lett"},{"key":"8795_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13046-025-03430-7","volume":"44","author":"W Zou","year":"2025","unstructured":"Zou W, Han Z, Wang Z, Liu Q. Targeting glutamine metabolism as a potential target for cancer treatment. J Exp Clin Cancer Res. 2025;44:180.","journal-title":"J Exp Clin Cancer Res"},{"key":"8795_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39:154\u201373.","journal-title":"Cancer Cell"},{"key":"8795_CR17","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1007\/s00262-023-03520-5","volume":"72","author":"KX Lin","year":"2023","unstructured":"Lin KX, Istl AC, Quan D, Skaro A, Tang E, Zheng X. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunol Immunother. 2023;72:3875\u201393.","journal-title":"Cancer Immunol Immunother"},{"key":"8795_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-022-01294-4","volume":"15","author":"J Weng","year":"2022","unstructured":"Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang Y, et al. Exploring immunotherapy in colorectal cancer. J Hematol Oncol. 2022;15:95.","journal-title":"J Hematol Oncol"},{"key":"8795_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e36550","volume":"10","author":"Z Su","year":"2024","unstructured":"Su Z, El Hage M, Linnebacher M. Mutation patterns in colorectal cancer and their relationship with prognosis. Heliyon. 2024;10:e36550.","journal-title":"Heliyon"},{"key":"8795_CR20","doi-asserted-by":"publisher","first-page":"2392341","DOI":"10.1080\/15384047.2024.2392341","volume":"25","author":"H Shan","year":"2024","unstructured":"Shan H, Tian G, Zhang Y, Qiu Z. Exploring the molecular mechanisms and therapeutic potential of SMAD4 in colorectal cancer. Cancer Biol Ther. 2024;25:2392341.","journal-title":"Cancer Biol Ther"},{"key":"8795_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Exp Clin Cancer Res. 2025;44:145.","journal-title":"J Exp Clin Cancer Res"},{"key":"8795_CR22","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/s43018-024-00807-z","volume":"5","author":"X Chu","year":"2024","unstructured":"Chu X, Li X, Zhang Y, Dang G, Miao Y, Xu W, et al. Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms. Nat Cancer. 2024;5:1409\u201326.","journal-title":"Nat Cancer"},{"key":"8795_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189281","volume":"1880","author":"F Ghorbaninezhad","year":"2025","unstructured":"Ghorbaninezhad F, Nour MA, Farzam OR, Saeedi H, Vanan AG, Bakhshivand M, et al. The tumor microenvironment and dendritic cells: Developers of pioneering strategies in colorectal cancer immunotherapy? Biochim Biophys Acta Rev Cancer. 2025;1880:189281.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8795_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104775","volume":"212","author":"E Chen","year":"2025","unstructured":"Chen E, Zhou W. Immunotherapy in microsatellite-stable colorectal cancer: Strategies to overcome resistance. Crit Rev Oncol\/Hematol. 2025;212:104775.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"8795_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1425596","volume":"15","author":"Z Huang","year":"2024","unstructured":"Huang Z, Li C, Huang Y, Liang W, Tao H. Efficacy and safety of PD-1\/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis. Front Immunol. 2024;15:1425596.","journal-title":"Front Immunol"},{"key":"8795_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.gastro.2024.02.025","volume":"167","author":"J Chen","year":"2024","unstructured":"Chen J, Feng W, Sun M, Huang W, Wang G, Chen X, et al. TGF-\u03b21-Induced SOX18 elevation promotes hepatocellular carcinoma progression and metastasis through transcriptionally upregulating PD-L1 and CXCL12. Gastroenterology. 2024;167:264\u201380.","journal-title":"Gastroenterology"},{"key":"8795_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116594","volume":"275","author":"J Yang","year":"2024","unstructured":"Yang J, Tian E, Chen L, Liu Z, Ren Y, Mao W, et al. Development and therapeutic perspectives of CXCR4 antagonists for disease therapy. Eur J Med Chem. 2024;275:116594.","journal-title":"Eur J Med Chem"},{"key":"8795_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00778-y","volume":"13","author":"A Rueda","year":"2025","unstructured":"Rueda A, Serna N, Mangues R, Villaverde A, Unzueta U. Targeting the chemokine receptor CXCR4 for cancer therapies. Biomark Res. 2025;13:68.","journal-title":"Biomark Res"},{"key":"8795_CR29","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41419-024-07210-7","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Yu T, Zhao Z, Li X, Song Y, He Y, et al. SMAD4 Limits PARP1 dependent DNA Repair to Render Pancreatic Cancer Cells Sensitive to Radiotherapy. Cell Death Dis. 2024;15:818.","journal-title":"Cell Death Dis"},{"key":"8795_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111878","volume":"41","author":"H-W An","year":"2022","unstructured":"An H-W, Seok SH, Kwon J-W, Choudhury AD, Oh J-S, Voon DC, et al. The loss of epithelial Smad4 drives immune evasion via CXCL1 while displaying vulnerability to combinatorial immunotherapy in gastric cancer. Cell Rep. 2022;41:111878.","journal-title":"Cell Rep"},{"key":"8795_CR31","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1002\/stem.1794","volume":"32","author":"S Khurana","year":"2014","unstructured":"Khurana S, Melacarne A, Yadak R, Schouteden S, Notelaers T, Pistoni M, et al. SMAD signaling regulates CXCL12 expression in the bone marrow niche, affecting homing and mobilization of hematopoietic progenitors. Stem Cells. 2014;32:3012\u201322.","journal-title":"Stem Cells"},{"key":"8795_CR32","doi-asserted-by":"publisher","first-page":"116930","DOI":"10.1016\/j.biopha.2024.116930","volume":"177","author":"W Zhang","year":"2024","unstructured":"Zhang W, Wang M, Ji C, Liu X, Gu B, Dong T. Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials. Biomed Pharmacother. 2024;177:116930.","journal-title":"Biomed Pharmacother"},{"key":"8795_CR33","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/gutjnl-2018-317163","volume":"69","author":"C Liang","year":"2020","unstructured":"Liang C, Shi S, Qin Y, Meng Q, Hua J, Hu Q, et al. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Gut. 2020;69:888\u2013900.","journal-title":"Gut"},{"key":"8795_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13046-024-02994-0","volume":"43","author":"B Wang","year":"2024","unstructured":"Wang B, Pei J, Xu S, Liu J, Yu J. A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle. J Exp Clin Cancer Res. 2024;43:74.","journal-title":"J Exp Clin Cancer Res"},{"key":"8795_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115529","volume":"44","author":"LK Do","year":"2025","unstructured":"Do LK, Lee HM, Ha YS, Lee CH, Kim J. Amino acids in cancer: Understanding metabolic plasticity and divergence for better therapeutic approaches. Cell Rep. 2025;44:115529.","journal-title":"Cell Rep"},{"key":"8795_CR36","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/cac2.12459","volume":"43","author":"X Hu","year":"2023","unstructured":"Hu X, Ma Z, Xu B, Li S, Yao Z, Liang B, et al. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. Cancer Commun. 2023;43:909\u201337.","journal-title":"Cancer Commun"},{"key":"8795_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2024.104896","volume":"137","author":"R Miyamoto","year":"2024","unstructured":"Miyamoto R, Takigawa H, Yuge R, Shimizu D, Ariyoshi M, Otani R, et al. Analysis of anti-tumor effect and mechanism of GLS1 inhibitor CB-839 in colorectal cancer using a stroma-abundant tumor model. Exp Mol Pathol. 2024;137:104896.","journal-title":"Exp Mol Pathol"},{"key":"8795_CR38","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.trecan.2021.04.003","volume":"7","author":"WH Yang","year":"2021","unstructured":"Yang WH, Qiu Y, Stamatatos O, Janowitz T, Lukey MJ. Enhancing the efficacy of glutamine metabolism inhibitors in cancer therapy. Trends Cancer. 2021;7:790\u2013804.","journal-title":"Trends Cancer"},{"key":"8795_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104536","volume":"10","author":"MA Gouda","year":"2025","unstructured":"Gouda MA, Voss MH, Tawbi H, Gordon M, Tykodi SS, Lam ET, et al. A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO open. 2025;10:104536.","journal-title":"ESMO open"},{"key":"8795_CR40","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/1535-7163.MCT-20-0430","volume":"20","author":"S Varghese","year":"2021","unstructured":"Varghese S, Pramanik S, Williams LJ, Hodges HR, Hudgens CW, Fischer GM, et al. The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies. Mol Cancer Ther. 2021;20:500\u201311.","journal-title":"Mol Cancer Ther"},{"key":"8795_CR41","doi-asserted-by":"crossref","unstructured":"Jeong H, Koh J, Kim S, Yim J, Song SG, Kim H, et al. Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer. J Immunother Cancer. 2025;13:e010612.","DOI":"10.1136\/jitc-2024-010612"},{"key":"8795_CR42","doi-asserted-by":"crossref","unstructured":"Ye J, Qin SS, Hughson AL, Hannon G, Salama NA, Vrooman TG, et al. Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models. J Immunother Cancer. 2025;13:e010820.","DOI":"10.1136\/jitc-2024-010820"},{"key":"8795_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89882-5","volume":"15","author":"NG Ciavattone","year":"2025","unstructured":"Ciavattone NG, Bevoor A, Farfel A, Rehman A, Ho KKY, Rock EC, et al. Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy. Sci Rep. 2025;15:5204.","journal-title":"Sci Rep"},{"key":"8795_CR44","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/hep.27665","volume":"61","author":"Y Chen","year":"2015","unstructured":"Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology. 2015;61:1591\u2013602.","journal-title":"Hepatology"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08795-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08795-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08795-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:05:38Z","timestamp":1782173138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08795-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8795"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08795-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The component of this study involving human participants was approved by the Ethics Committee of Bengbu Medical University (Approval No. [2025] 166), and written informed consent was obtained from all participants. The animal experiments were approved by the Animal Ethics Committee of Bengbu Medical University (Approval No. [2025] 495). All procedures were conducted in accordance with the ARRIVE guidelines and complied with national and institutional regulations for the care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"591"}}